explore -WSS

explore

author：entertainment 2025-10-01 21:37:34 - browse：181

An artist's rendering of the building — currently under construction along Boston's Fort Point Channel — where Eli Lilly plans to open its Institute for Genetic Medicine. Courtesy Alexandria Real Estate Equities Inc

Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the world’s hottest pharmaceutical companies, said this week that the genetic medicine research center it plans to open in Boston in August will eventually employ twice as many workers as originally estimated.

In February 2022, Lilly said that it would increase its modest Massachusetts workforce from 120 to 250 employees when it opened the $700 million Lilly Institute for Genetic Medicine along Fort Point Channel. The Indianapolis-based company said it would move 120 scientists from Kendall Square in Cambridge to the institute and add another 130.

But Daniel Skovronsky, Lilly’s chief scientific and medical officer, said in an interview that the 12-story, 334,000-square-foot laboratory and office building will ultimately accommodate 500 Lilly scientists and researchers.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： What to expect at HLTH 2023, the health care industry conference

WSS

Leukemia patients are helped by Syndax's new type of therapy

FDA authorizes Novavax’s updated Covid

Bill would stop addiction treatment from triggering child abuse inquiry

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Chemotherapy drug shortage eases slightly but still widespread

Patients' immediate access to test results puts radiologists in a bind

entertainment

explore

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Pregnancy discrimination could be enabled by AI

Peter Hotez and the public health issue of online harassment

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Novavax promises a turnaround & Lilly roils the obesity market

Why sickle cell disease is getting the first CRISPR treatment

The high cost of giving birth even with insurance

Pfizer plans to depart BIO

Peter Hotez and the public health issue of online harassment

Was Amgen transparent enough on FDA's concern on cancer drug?

focus

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Colorectal cancer study finds potential in overlooked immune cell

Leukemia patients are helped by Syndax's new type of therapy

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Liquid biopsy for lung cancer is launched by Delfi

Histogen: Failed biotech offers rare public look inside

leisure time

entertainment

hotspot

leisure time